What Biolinco does

Biolinco is a privately held biotechnology services company founded in 2023 and headquartered in Baltimore, Maryland. The company provides high-throughput cell line development services to Contract Development and Manufacturing Organizations (CDMOs) and biopharmaceutical companies, targeting the critical bottleneck of clone selection for biologic drug manufacturing. Its core offering is the MATCH Platform, a barcoded cell line development platform that combines unique, heritable DNA barcodes with multi-omic characterization (FACS-based assays and sequencing) to screen thousands of Chinese Hamster Ovary (CHO) cell clones simultaneously in a single fed-batch run under manufacturing-relevant conditions.

Technically, the MATCH workflow assigns a unique DNA barcode to each cell line, pools thousands of barcoded clones into a manufacturing-scale fed-batch culture, characterizes productivity and quality for every clone in parallel, and then retrieves top clones with >99.8% on-target precision, outputting a manufacturing-ready cell line with a full performance dataset. The platform claims to screen >2,500x more clones per run than conventional 96-well plate methods, support libraries of >200,000 unique barcodes, and reduce cost per clone by 100-1,000x. Biolinco's scientific founders (Kent Rapp, Kevin Wen, Reza Kalhor, Michael Betenbaugh) are all PhD researchers from Johns Hopkins University, and the company has been backed by Johns Hopkins-affiliated accelerators (FastForward U, JHTV) and selected into the Techstars Spring 2026 cohort.

Commercially, Biolinco operates a direct enterprise sales model with quote-based, project-fee pricing on cell line development engagements. It has no publicly disclosed customers, revenue, or institutional funding rounds, and has not published pricing. Marketing is conducted through the company website, accelerator demo days (Techstars Spring 2026, JHU Innovation Summit, FastForward U Spark Showcase), and a direct contact form — indicating a company at an early, pre-commercial or pilot-stage phase focused on customer development and fundraising.

Name

Biolinco

Legal name

Biolinco Inc.

Website

https://biolinco.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

Biolinco is a Baltimore-based biotech services company founded in 2023 that uses its MATCH Platform — combining DNA barcoding with multi-omic characterization — to provide high-throughput cell line development services to CDMOs and biopharmaceutical manufacturers seeking better clone selection.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Cell Line Development Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF)

akta.pro secondary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Cell line development
• Biopharmaceutical manufacturing
• DNA barcoding technology
• CHO cell screening
• Biologic drug development

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Cell Line Development Services: Biolinco provides cell line development services to CDMOs and biopharmaceutical companies. The company screens cell lines for clients using their barcoded platform, generating revenue through service fees for custom cell line development projects.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Biolinco provides high-throughput cell line development services through its proprietary MATCH Platform, which uses DNA barcoding combined with multi-omic characterization to screen thousands of CHO cell clones simultaneously under real manufacturing conditions. The platform delivers manufacturing-ready cell lines with comprehensive performance datasets to CDMOs and biopharmaceutical companies, enabling better-informed clone selection decisions before scale-up.

Product overview

Biolinco offers a single unified platform — the MATCH Platform — for high-throughput cell line development services. The platform combines DNA barcoding with multi-omic characterization to screen thousands of barcoded CHO cell clones simultaneously under real manufacturing conditions. Biolinco provides cell line development services for CDMOs and biopharmaceutical companies, with the platform capable of screening over 200,000 unique barcodes per library, delivering 2,500x more clones screened per run compared to conventional 96-well plate methods.

Differentiator

Problem solved

Functional benefit

Products and services

• MATCH Platform

Quantifiable outcome

• Screens >2,500x more clones per run compared to conventional 96-well plate methods
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators5 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• Lonza: One of the world's largest CDMOs with a long-established mammalian cell line development (e.g., GS Xceed) service for biopharma. Directly comparable as a CLD service provider to Biolinco's CDMO and biopharma customers, though operating at vastly greater scale and as part of a full-service CMC portfolio.
• Cytiva: Supplies cell line development tools, media, and services used by CDMOs and biopharma for CHO-based biologics manufacturing. Comparable as a CLD-enabling technology and services provider serving the same customer base.
• Samsung Biologics: Large-scale biologics CDMO with integrated cell line development, process development, and manufacturing services. Comparable as a CLD/CDMO competitor to Biolinco's biopharma customers.
• AGC Biologics: Global CDMO providing cell line development, process development, and GMP manufacturing for biologics. Comparable as a CLD/CDMO competitor, particularly to mid-sized biopharma programs.
• WuXi Biologics: Global biologics CDMO offering cell line development, process development, and manufacturing. Overlaps with Biolinco on the CLD step for biopharma clients, but delivers it as part of a much broader end-to-end CMC platform.
• FUJIFILM Diosynth Biotechnologies: Major biologics CDMO offering cell line development and manufacturing services. Comparable as a CLD provider to CDMOs and biopharma, embedded within a broader CMC offering.

Direct peers

• Berkeley Lights (now PhenomeX): Developed single-cell screening and functional cell selection platforms used in cell line development and biologics discovery. Closely comparable in the technology play — using single-cell/functional screening to improve clone selection — though with a different hardware-centric delivery model.
• KBI Biologics: Mid-sized CDMO with cell line development, process development, and analytical services for biopharma. Comparable as a CLD-focused service provider to biopharma clients, more similar in scale and positioning than the mega-CDMOs.
• AbCellera Biologics: Uses high-throughput single-cell screening and genomics to discover and engineer antibody and protein therapeutics. Comparable as a technology-driven, high-throughput biologics discovery/development company serving biopharma, though focused on antibody discovery rather than upstream CLD.

Others

• 10x Genomics: Provides single-cell sequencing and multi-omic characterization platforms that overlap with Biolinco's underlying multi-omic characterization workflow. An enabling/adjacent technology provider rather than a direct CLD competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biolinco